Novo Nordisk ultrafast acting insulin drug FIASP is to be withdrawn from the Australian Pharmaceutical Benefits Scheme (PBS) on April 1, 2023. This means for insulin users the price will climb from $A8 per month to $A230 making it unaffordable to many. Credit Stephen Dwyer Alamy Live News
GLIX-115-2P6XMT3
EDITORIAL LICENC
Kizárólag sajtó felhasználásra.
Kizárólag sajtó felhasználásra.
A képet csak az alábbi országokban használhatja fel:
Magyarország
Magyarország
NEM engedélyezett felhasználási módok:
personalUse advertisingCommercialUse commercialElectronicUse consumerGoodsUse directMailBrochuresUse indoorDisplayUse internalBusinessUseKollekció
GLIX Prime
Contains property
Fotós / Szerző
Stephen Dwyer
Készült
Leírás
Novo Nordisk ultrafast acting insulin drug FIASP is to be withdrawn from the Australian Pharmaceutical Benefits Scheme (PBS) on April 1, 2023. This means for insulin users the price will climb from $A8 per month to $A230 making it unaffordable to many. Credit Stephen Dwyer Alamy Live News
Kulcsszavak
australian pbs listed drug,
blood glucose control,
diabetes care,
diabetes equipment,
diabetes management,
diabetes medication,
diabetes supplies,
diabetes treatment,
fast acting insulin,
for type1 diabetics,
health care for chronic illness,
injection device,
insulin delivery,
insulin dosage,
insulin injection,
insulin pen device,
insulin pen tips,
novo nordisk fiasp,
pharmaceutical supplies,
short term acting insulin,
type 1 diabetes sufferers,
ultra fast insulin drug,